retatrutide clinical trials sign up A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide Results: 28.3% Weight Loss

A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes

Despite GLP-1 concentration being higher in the fundus than the antrum, its release ex vivo upon IBMX stimulation increases to the same extent in both the fundus and antrum, suggesting a significant contribution to both portal and gastric GLP-1 (Ribeiro-Parenti et al., 2021)

Unlike patients with diabetes, many of whom are well-acquainted with managing complex medication regimens, GLP-1 users for weight loss are often new to injecting and may have different levels of medical literacy, motivations and expectations

Doctors usually prescribe a lower dose to start with and work up to a full-strength dose over several months to minimize side effects

Moreover, mice with obesity exhibited impaired intestinal structure, marked by damage to the morphology of small intestinal villi, reduced villus length, and a decrease in the number of goblet cells and the thickness of the mucus layer 6